Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Withdrawn Phase 3 Interventional

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

ClinicalTrials.gov ID: NCT01605084

Public ClinicalTrials.gov record NCT01605084. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the proportion of subjects with HIV-1 RNA \< 50 c/mL at Week 48 in patients who failed their first line therapy containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor

Study identification

NCT ID
NCT01605084
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
Not listed

Conditions and interventions

Conditions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2012
Primary completion
Aug 30, 2014
Completion
Aug 30, 2014
Last update posted
Dec 18, 2023

2012 – 2014

United States locations

U.S. sites
14
U.S. states
8
U.S. cities
11
Facility City State ZIP Site status
Southwest Center For Hiv/Aids Phoenix Arizona 85006
Southwest Center For Hiv/Aids Phoenix Arizona
Health For Life Clinic Pllc Little Rock Arkansas 72207
Anthony M. Mills Md Inc Los Angeles California 90069
Uc Davis Medical Center Sacramento California 95817
Metropolis Medical Pc San Francisco California 94109
Indiana University Hospital Indianapolis Indiana 46202
Be Well Medical Center Berkley Michigan
Southampton Health Center St Louis Missouri 63139
Southampton Health Center St Louis Missouri
I.D. Care Associates Hillsborough New Jersey 08844
Saint Michael'S Medical Center Newark New Jersey 07102
James J Peters VAMC The Bronx New York 10468
Infectious Disease Clinic & AI The Bronx New York

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01605084, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 18, 2023 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01605084 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →